title: [Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus].
abstract: OBJECTIVE
  To compare the efficacies of portal vein stenting and transcatheter arterial chemoembolization (TACE) combined therapy performed with or without endovascular implantation of iodine-125 (125I) seeds strand in patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombus (MPVTT).
  
  
  METHODS
  One-hundred-and-six patients with HCC complicated by MPVTT who were treated with portal vein stents and TACE, either with (Group A, n=56) or without (Group B, n=50) endovascular implantation of 125I seeds strand, between July 2005 and April 2011, were retrospectively analyzed. Overall survival, stent patency, and procedure-related adverse events were compared between the two groups.
  
  
  RESULTS
  The technical success rate was 100% for placement of 125I seeds strands and stents in the obstructed main portal vein. No serious procedure-related adverse events were recorded. Group A had significantly higher median survival (335 days vs. group B: 146 days; P=0.001, hazard ratio (HR)=2.244). Additionally, group A had significantly higher median stent patency (400 days vs. group B: 190 days; P=0.005, HR=2.479).
  
  
  CONCLUSIONS
  The combination therapeutic strategy of portal vein stenting and TACE with endovascular implantation of 125I seeds strands improves the survival of HCC patients with MPVTT complication.
authors.affiliation: Fudan University, Shanghai, China.
authors.forename: Lin-lin
authors.initials: LL
authors.lastname: Wu
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Luo
authors.forename: Zhi-ping
authors.initials: ZP
authors.lastname: Yan
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Wang
authors.forename: Xiao-lin
authors.initials: XL
authors.lastname: Wang
authors.forename: Xue-bin
authors.initials: XB
authors.lastname: Zhang
authors.forename: Zhu-ting
authors.initials: ZT
authors.lastname: Fang
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein / Q000503:physiopathology / Q000601:surgery; D012189:Retrospective Studies; D015607:Stents; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000150:complications / Q000628:therapy
chemical_list: D007457:Iodine Radioisotopes